Immune checkpoint blocking by monoclonal antibodies appeared as a successful treatment for patient with melanoma which targets cytotoxic T lymphocyte antigen (CTLA-4) directly, for instance, Ipilimumab that targets PD-1 and PDL-1. Here, CTLA4 is linked to melanoma.